A phase 2, randomized, double-blind, placebo-controlled ST of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY)

Medicine & Life Sciences

• pimavanserin 100%
• Major Depressive Disorder 56%
• Placebos 37%
• Serotonin and Noradrenaline Reuptake Inhibitors 27%
• Serotonin Uptake Inhibitors 22%
• Least-Squares Analysis 15%
• Therapeutics 8%
• Serotonin Antagonists 8%
• Nausea 5%
• Mouth 5%
• Headache 5%
• Depression 4%
• Safety 3%